The other three subtypes, as well as melanoma of unknown primary, were, as mentioned above, dominated by driver mutations in the genes of the cell cycle control (CDKN2A) and the RTK/RAS signaling pathway (BRAF, NRAS, ERRB2). Here, NRAS is linked to melanoma.